NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

367.45 -4.65 (-1.25%)

26.27% Gain from 52W Low

1.1M NSE+BSE Volume

NSE 08 Jul, 2025 11:58 AM (IST)

49,126.7

Market Cap

Market Leader

1.2

Beta 1Year

High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Biocon Ltd.

07 Feb 2022, 12:00AM

367.45

-1.25%

BIOCON LTD

Buy: Biocon Ltd.

Target

Geojit BNP Paribas

Consolidated revenue for Q3FY22 was up 17.1% YoY to Rs. 2,174cr (+18.1% QoQ), driven by a strong performance across all business segments. Biggest contributor to the revenue growth was the Biosimilars business. Biocon Biologics Ltd. recorded revenue of Rs. 981cr, a growth of 27.6% YoY (+32.2% QoQ) helped by robust demand across products and geographies and the launch of 351(k) biosimilar Insulin Glargine in the *over or under performance to benchmark index...

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

24 Jan 2022

367.45

-1.25%

BIOCON LTD

Accumulate: Biocon Ltd.

Recommendation Target

Hem Securities

Revenue at Rs 2,223 Cr for Q3FY22, up 18%; EBITDA at Rs. 537 Cr, up 28%. Generics - three new approvals, partnership with Tabuk Pharmaceuticals for expansion into the Middle East and North Africa. Biosimilars - interchangeable bGlargine launched in US and received...

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

24 Jan 2022

367.45

-1.25%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

Therefore, we recommend a BUY rating with a Target Price of Rs 425, implying an upside of 14% from the CMP.

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

21 Jan 2022

367.45

-1.25%

Biocon

Hold: Biocon Ltd.

Target

ICICI Securities Limited

What should investors do? Biocon's share price has grown by ~2.3x over the past five years (from ~| 162 in January 2017 to ~| 370 levels in January 2022). We maintain HOLD as we await continuity in biosimilars momentum besides...

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon Ltd.

06 Dec 2021

367.45

-1.25%

On course to revive earnings growth

Neutral: Biocon Ltd.

Motilal Oswal

In addition to steady traction in already launched Biosimilars, BIOS has Insulin Glargine (Semglee) contracts starting 4QFY22. This would be further supported by bAspart, subject to regulatory clearance. The recent agreement with the Serum Institute of India (SII) to market its COVID-19 vaccine further increases its business prospects from 2HFY23E onwards. We expect 36% earnings CAGR over FY21-23E, led by Insulin Glargine, scaling up of the Biologics business in emerging markets, and ramp-up in research services. We are yet to factor in the Vaccine business in our estimates. While the earnings outlook remains promising, we maintain our Neutral stance with a...

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

09 Nov 2021

367.45

-1.25%

Axis Annual Analysis:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We expect revenue and PAT CAGR of 11.4% and 16.0% respectively over the period FY21-FY24E and we recommend a BUY on the stock with TP of Rs 390, implying an upside of 12% from CMP.

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

28 Oct 2021

367.45

-1.25%

BIOCON LTD

Buy: Biocon Ltd.

Target

Geojit BNP Paribas

The company's medium-term outlook remains intact on new product launches, new approvals from US FDA, increased R&D; spends, strong pipeline and higher operational efficiency. Therefore, we reiterate our...

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

25 Oct 2021

367.45

-1.25%

Result Update:Biocon

Buy: Biocon Ltd.

Recommendation Target

Axis Direct

We believe the company's valuations are at a comfortable level considering the its stable growth over a longer period. Therefore, we recommend BUY with a Target Price of Rs 370.

Biocon Ltd. is trading above all available SMAs

Biocon Ltd.

23 Oct 2021

367.45

-1.25%

Ramp-up in Biosimilars offset by lower Generic sales

Neutral: Biocon Ltd.

Target

Motilal Oswal

BIOS delivered an operationally in line 2QFY22, while higher other income led the earnings beat. The healthy show in Research Services and ramp-up in Biosimilar sales was dragged down by the Generics segment on a YoY basis. We lower our FY23E EPS estimate by 3%, factoring in: a) pandemic-led delays in inspection, thereby having a subsequent impact on the approval timeline, b) gradual pick-up in market share for Insulin Glargine c) intense pricing pressure in Generics, and d) an increase in raw material prices. We value BIOS at 32x 12-month forward earnings to arrive at our TP of...

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Biocon Ltd.

22 Oct 2021

367.45

-1.25%

Biocon

Hold: Biocon Ltd.

Target

ICICI Securities Limited

Robust biosimilar portfolio with partners like Viatris, Sandoz (for future launches), Adagio among others. Biosimilar US pipeline: (Approvals Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab. Global footprint in +120 countries for biosimilars In generics, it is among the world's...

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

Is Biocon Ltd. worth buying?

721 Votes:

Buy 75.03%

Sell 16.23%

Hold 8.74%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf